Table 2.
Health Benefits, Costs, and Incremental Cost-Effectiveness Ratio from Statin Therapy for Patients with Different Age, Sex, and Cardiovascular Risk Profiles
| Starting Age | 10-Year Probability of MI1 % | Increased Cost ($) | Gain in QALYs (discounted) | Increased life expectancy (undiscounted) (months) | Reduced risk of MI or stroke (percent)2 | Incremental cost-effectiveness ratio ($/QALY) |
|---|---|---|---|---|---|---|
| Men | ||||||
| 50 | 6 | 1,700 | 0.09 | 1.6 | 4.4 | 20,500 |
| 55 | 10 | 1,800 | 0.09 | 1.7 | 4.8 | 19,600 |
| 60 | 12 | 1,800 | 0.10 | 1.7 | 5.0 | 18,900 |
| 65 | 16 | 1,800 | 0.10 | 1.6 | 5.1 | 18,000 |
| 70 | 17 | 1,500 | 0.09 | 1.5 | 5.0 | 16,900 |
| 75† | 20 | 1,300 | 0.08 | 1.2 | 4.7 | 16,300 |
| 80† | 20 | 900 | 0.06 | 0.9 | 4.1 | 16,100 |
| 85† | 20 | 600 | 0.04 | 0.6 | 3.3 | 15,400 |
| Women | ||||||
| 50 | 1 | 1,700 | 0.03 | 0.7 | 2.1 | 56,800 |
| 55 | 2 | 1,800 | 0.04 | 0.9 | 2.6 | 46,200 |
| 60 | 3 | 1,900 | 0.05 | 1.0 | 3.1 | 39,200 |
| 65 | 5 | 1,900 | 0.06 | 1.1 | 3.5 | 33,400 |
| 70 | 8 | 1,700 | 0.06 | 1.1 | 3.7 | 29,300 |
| 75 | 14 | 1,400 | 0.06 | 1.1 | 3.8 | 25,000 |
| 80 | 14 | 1,100 | 0.05 | 0.9 | 3.6 | 21,300 |
| 85 | 14 | 700 | 0.04 | 0.6 | 3.0 | 19,800 |
For more detailed results see Supplement Table S5. Because costs are rounded to the nearest $100, incremental cost-effectiveness ratios may be slightly different than the incremental costs and QALYs in the table suggest.
Based from a Framingham risk score(19)
Combined reduction in myocardial infarction (MI) and stroke before development of end-stage renal disease
ATPIII currently recommends that individuals with risk level of 20% or more should be treated with statins. All other groups of CKD patients in the table would not have statin therapy currently recommended if they had no other CV risk equivalents.